Johnson & Johnson (NYSE:JNJ) Stock Position Lowered by Beaumont Financial Advisors LLC

Beaumont Financial Advisors LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 125,953 shares of the company’s stock after selling 2,260 shares during the quarter. Johnson & Johnson accounts for 1.6% of Beaumont Financial Advisors LLC’s investment portfolio, making the stock its 22nd biggest holding. Beaumont Financial Advisors LLC’s holdings in Johnson & Johnson were worth $20,412,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Innealta Capital LLC purchased a new position in Johnson & Johnson during the second quarter valued at approximately $27,000. MFA Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the second quarter worth $43,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Johnson & Johnson during the second quarter worth $46,000. Grayhawk Investment Strategies Inc. boosted its position in Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after purchasing an additional 259 shares during the last quarter. Finally, Fairway Wealth LLC grew its stake in Johnson & Johnson by 217.1% in the second quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock valued at $49,000 after purchasing an additional 228 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Morgan Stanley lifted their price target on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Thursday. TD Cowen cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Royal Bank of Canada upped their price objective on shares of Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $173.43.

Johnson & Johnson Trading Down 0.1 %

Shares of Johnson & Johnson stock opened at $160.52 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company’s fifty day simple moving average is $162.64 and its 200-day simple moving average is $154.45. The company has a market cap of $386.41 billion, a price-to-earnings ratio of 10.03, a PEG ratio of 2.65 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the business posted $2.80 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.09%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.98%.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.